Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

, MRK

Merck

09:13
10/10/16
10/10
09:13
10/10/16
09:13

JPMorgan Euro & US pharma/biotech analysts hold analyst/industry conference call

European Healthcare Analysts Vosser and Gordon, along with U.S. and Specialty Pharmaceuticals Analyst Schott, discuss key takeaways from the European Society for Medical Oncology (ESMO) Conference on an Analyst/Industry conference call to be held on October 10 at 10 am.

BMY

Bristol-Myers

MRK

Merck

RHHBY

Roche

$30.49

-0.05 (-0.16%)

AZN

AstraZeneca

  • 19

    Oct

  • 25

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

  • 10

    Nov

  • 16

    Nov

BMY Bristol-Myers

09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
MRK Merck

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
RHHBY Roche
$30.49

-0.05 (-0.16%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
AZN AstraZeneca

09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
AstraZeneca initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started AstraZeneca with an Overweight rating and GBP 60 price target.
10/07/16
PIPR
10/07/16
NO CHANGE
PIPR
Neutral
Piper still sees Clovis' rucaparib getting broader indication than Lynparza
Piper Jaffray analyst Steven Breazzano said the rucaparib response rates in platinum resistant and platinum refractory patients of 25% and 0%, respectively, reported by Clovis Oncology (CLVS) are lower than some may have been expecting and "seemingly negative on the surface." However, he continues to believe rucaparib will be approved in BRCA patients who have received 2+ lines of therapy, which is an earlier and broader patient population than assigned to competitor AstraZeneca's (AZN) Lynparza, he tells investors. The ultimate market potential and key to success is the maintenance setting, for which TESARO's (TSRO) niraparib is still best-positioned, adds Breazzano, who keeps a Neutral rating on Clovis shares.
09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Neutral
AstraZeneca downgraded to Neutral from Outperform at Exane BNP Paribas

TODAY'S FREE FLY STORIES

CIVB

Civista

$22.15

0.04 (0.18%)

21:13
02/21/17
02/21
21:13
02/21/17
21:13
Syndicate
Civista 1.4M share Secondary priced at $21.75 »

Keefe Bruyette and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TJX

TJX

$76.24

-0.95 (-1.23%)

, SO

Southern Company

$48.28

0.48 (1.00%)

20:25
02/21/17
02/21
20:25
02/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TJX

TJX

$76.24

-0.95 (-1.23%)

SO

Southern Company

$48.28

0.48 (1.00%)

DISH

DISH

$62.82

-0.07 (-0.11%)

HST

Host Hotels

$18.69

0.3 (1.63%)

NCLH

Norwegian Cruise Line

$48.20

0.51 (1.07%)

MBLY

Mobileye

$46.12

0.47 (1.03%)

GRMN

Garmin

$50.45

-0.36 (-0.71%)

TOL

Toll Brothers

$31.99

0.5 (1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

MNTA

Momenta

20:19
02/21/17
02/21
20:19
02/21/17
20:19
Downgrade
Momenta rating change  »

Momenta downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

MNTA

Momenta

$16.05

-2.95 (-15.53%)

20:19
02/21/17
02/21
20:19
02/21/17
20:19
Downgrade
Momenta rating change  »

Momenta downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SNAP

Snap Inc

20:00
02/21/17
02/21
20:00
02/21/17
20:00
Periodicals
Goldman Sachs: Snap revenue could hit $2B in 2018, Business Insider reports »

Goldman Sachs, one of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

BA

Boeing

$175.56

2.85 (1.65%)

19:55
02/21/17
02/21
19:55
02/21/17
19:55
Periodicals
Boeing attempts to accelerate satellite manufacturing process, WSJ says »

Boeing is working to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

DBOEY

Deutsche Boerse

$8.64

0.065 (0.76%)

19:50
02/21/17
02/21
19:50
02/21/17
19:50
Periodicals
Deutsche Boerse, LSE set to offer additional merger concessions, FT says »

Deutsche Boerse and LSE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$133.72

0.19 (0.14%)

19:35
02/21/17
02/21
19:35
02/21/17
19:35
Periodicals
Facebook nears deal to expand European headquarters, Bloomberg says »

Facebook is nearing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 28

    Mar

GOOG

Alphabet

$831.66

3.59 (0.43%)

, GOOGL

Alphabet Class A

$849.27

2.72 (0.32%)

19:25
02/21/17
02/21
19:25
02/21/17
19:25
Periodicals
Google to discontinue 'Google Site Search,' Fortune says »

Google plans to…

GOOG

Alphabet

$831.66

3.59 (0.43%)

GOOGL

Alphabet Class A

$849.27

2.72 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

  • 06

    Mar

  • 19

    Mar

WMT

Wal-Mart

$71.45

2.08 (3.00%)

19:20
02/21/17
02/21
19:20
02/21/17
19:20
Periodicals
Wal-Mart adds some in-house brands to Jet.com, Bloomberg says »

Wal-Mart subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

AAPL

Apple

$136.70

0.98 (0.72%)

19:13
02/21/17
02/21
19:13
02/21/17
19:13
Hot Stocks
Analytics firm: Average U.S. iPhone user spent $40 on apps in 2016 »

Analytics firm Sensor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

AMZN

Amazon.com

$856.44

11.37 (1.35%)

19:05
02/21/17
02/21
19:05
02/21/17
19:05
Periodicals
Amazon to sell beer, wine in 'Amazon Go' store, Recode says »

Amazon plans to sell beer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 14

    Mar

  • 19

    Mar

  • 28

    Mar

ARII

American Railcar

$46.03

-0.62 (-1.33%)

, IEP

Icahn Enterprises

$54.95

-1.03 (-1.84%)

19:01
02/21/17
02/21
19:01
02/21/17
19:01
Hot Stocks
American Railcar enters Consulting Services pact with American Railcar Leasing »

According to a regulatory…

ARII

American Railcar

$46.03

-0.62 (-1.33%)

IEP

Icahn Enterprises

$54.95

-1.03 (-1.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

FB

Facebook

$133.72

0.19 (0.14%)

, TWTR

Twitter

$16.42

-0.2 (-1.20%)

18:57
02/21/17
02/21
18:57
02/21/17
18:57
Periodicals
MLB in talks with Facebook to stream one game per week, Reuters says »

Facebook (FB) is in…

FB

Facebook

$133.72

0.19 (0.14%)

TWTR

Twitter

$16.42

-0.2 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 28

    Mar

TX

Ternium

$23.69

0.13 (0.55%)

, TYEKF

ThyssenKrupp

18:50
02/21/17
02/21
18:50
02/21/17
18:50
Hot Stocks
Ternium to acquire CSA Siderurgica from ThyssenKrupp »

Ternium (TX) announced a…

TX

Ternium

$23.69

0.13 (0.55%)

TYEKF

ThyssenKrupp

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTB

Butterfield

$32.93

-0.08 (-0.24%)

, CG

Carlyle Group

$16.20

0.15 (0.93%)

18:30
02/21/17
02/21
18:30
02/21/17
18:30
Syndicate
Butterfield announces offering of 9.56M shares of common stock for holders »

The Bank of N.T.…

NTB

Butterfield

$32.93

-0.08 (-0.24%)

CG

Carlyle Group

$16.20

0.15 (0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

CPRT

Copart

$60.30

1.29 (2.19%)

18:09
02/21/17
02/21
18:09
02/21/17
18:09
Earnings
Copart reports Q2 adjusted EPS 58c, consensus 57c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

DAL

Delta Air Lines

$51.21

-0.02 (-0.04%)

18:07
02/21/17
02/21
18:07
02/21/17
18:07
Hot Stocks
Aeromexico says concludes Delta tender offer 'represents fair value' »

Grupo Aeromexico issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSS

Golden Star Resources

$0.99

0.0232 (2.40%)

18:04
02/21/17
02/21
18:04
02/21/17
18:04
Hot Stocks
Golden Star Resources sees FY17 gold production 255,000-280,000 »

Sees FY17 AISC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

GSS

Golden Star Resources

$0.99

0.0232 (2.40%)

17:57
02/21/17
02/21
17:57
02/21/17
17:57
Earnings
Golden Star Resources reports Q4 adjusted EPS 1c, consensus (1c) »

Reports Q4 gold revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CY

Cypress Semiconductor

$13.12

0.22 (1.71%)

17:52
02/21/17
02/21
17:52
02/21/17
17:52
Hot Stocks
Cypress Semiconductor founder nominates two candidates for board »

T.J. Rodgers, founder and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 16

    Mar

XPO

XPO Logistics

$48.38

-0.84 (-1.71%)

, DEPO

Depomed

$15.77

-0.7 (-4.25%)

17:41
02/21/17
02/21
17:41
02/21/17
17:41
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: XPO…

XPO

XPO Logistics

$48.38

-0.84 (-1.71%)

DEPO

Depomed

$15.77

-0.7 (-4.25%)

WMGI

Wright Medical

$26.86

-0.1 (-0.37%)

HCLP

Hi-Crush Partners

$21.40

0.1 (0.47%)

RRGB

Red Robin

$47.50

-0.3 (-0.63%)

FSLR

First Solar

$36.62

1.78 (5.11%)

LNTH

Lantheus

$9.35

-0.1 (-1.06%)

GE

General Electric

$30.52

0.15 (0.49%)

TRCO

Tribune Media

$33.70

0.73 (2.21%)

SREV

ServiceSource

$6.05

0.22 (3.77%)

FUEL

Rocket Fuel

$2.55

0.08 (3.24%)

TXRH

Texas Roadhouse

$47.79

-0.45 (-0.93%)

WLL

Whiting Petroleum

$11.57

0.46 (4.14%)

TEX

Terex

$32.13

0.13 (0.41%)

PZZA

Papa John's

$85.63

-0.38 (-0.44%)

FE

FirstEnergy

$31.33

0.32 (1.03%)

PKD

Parker Drilling

GBT

Global Blood Therapeutics

$28.50

1.6 (5.95%)

CUZ

Cousins Properties

$8.66

0.01 (0.12%)

YUM

Yum! Brands

$67.67

-0.73 (-1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 07

    Mar

  • 07

    Mar

  • 14

    Mar

  • 26

    Apr

  • 09

    May

  • 22

    Feb

GLA

GlassBridge

, IMN

Imation

$0.77

-0.0091 (-1.17%)

17:41
02/21/17
02/21
17:41
02/21/17
17:41
Hot Stocks
GlassBridge implements name change, reverse stock split »

GlassBridge Enterprises…

GLA

GlassBridge

IMN

Imation

$0.77

-0.0091 (-1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HVT

Haverty Furniture

$22.95

0.4 (1.77%)

17:37
02/21/17
02/21
17:37
02/21/17
17:37
Earnings
Haverty Furniture reports Q4 EPS 51c, consensus 43c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CUZ

Cousins Properties

$8.66

0.01 (0.12%)

17:36
02/21/17
02/21
17:36
02/21/17
17:36
Syndicate
Breaking Syndicate news story on Cousins Properties »

Cousins announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.